Strides Arcolab enters into strategic partnership with Eli Lilly

05 Dec 2012 Evaluate

Strides Arcolab has entered into a partnership with Eli Lilly and Company to expand delivery of cancer medicines in the emerging market. As a part of this arrangement, Lilly will in-license a portfolio of high-quality, branded generic injectable and oral cancer medicines from Agila specialties, division of strides Acrolab, based in Bangalore, India.

Agila Specialties will manufacture the cancer medicines, and Lilly will register and market these medications in multiple geographies across the emerging market. In addition to the initial 10 medicines   included as part of the agreement, Lilly has the right to add additional high-quality branded generic oncology to the portfolio in the future.

Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.

Strides Pharma Scien Share Price

796.20 -68.60 (-7.93%)
23-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1631.65
Dr. Reddys Lab 1235.15
Cipla 1314.85
Zydus Lifesciences 881.95
Lupin 2137.15
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×